Abstract
Gastroesophageal reflux disease and other related symptoms are common comorbidities for HIV-infected patients. Therefore, concurrent use of proton pump inhibitors and antiretrovirals is a common practice in the clinical setting. However, this practice may alter antiretroviral pharmacokinetics and lead to treatment failure due to inadequate drug exposure. Clinician awareness of these complex interactions is essential for optimal HIV management. This review summarizes the current knowledge on the interactions between proton pump inhibitors and antiretrovirals, and makes recommendations for the coadministration of proton pump inhibitors.
Acknowledgements
GD Morse is supported in part by grant #5R01DA015024-02 from the National Institute on Drug Abuse and #5UO1A127658-16 from the National Institute of Allergy and Infectious Diseases. S McCabe is a UB-Novartis Drug Development Fellow.